SEC Form 4 · accession 0001209191-15-054363
Anacor Pharmaceuticals, Inc. · ANAC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lee Zane
Officer — SVP and Chief Medical Officer
Period of report
Jun 15, 2015
Accepted (ET)
Jun 17, 2015 · 6:56 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001411158
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 15, 2015 | M | 4,339 | $5.59 | A | 32,495 | D | |
| Common StockF2 | Jun 15, 2015 | S | 4,339 | $69.0492 | D | 28,156 | D | |
| Common Stock | Jun 15, 2015 | M | 7,661 | $6.92 | A | 35,817 | D | |
| Common StockF2 | Jun 15, 2015 | S | 7,661 | $69.0492 | D | 28,156 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $5.59 | Jun 15, 2015 | M | 4,339 | D | — | Mar 13, 2022 | Common Stock | 4,339 | 55,661 | D |
| Stock Option (right to buy)F4 | $6.92 | Jun 15, 2015 | M | 7,661 | D | — | Mar 31, 2021 | Common Stock | 7,661 | 33,239 | D |
Explanation of responses
- F1This sale was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person.
- F2The price reported in Column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $68.51 to $69.50, inclusive.
- F31/4 of the shares subject to the option shall vest and become exercisable on the one-year anniversary of the Vesting Commencement Date, which is January 1, 2012, and 1/48 of the shares subject to the option shall vest and become exercisable each month thereafter.
- F4This option is fully vested and exercisable.